Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Mainstay Medical Limited

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Mainstay Medical Limited

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Mainstay Medical Limited. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jun 16, 2020 to Oct 19, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code QLK appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P190021, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: Clonmel House Forster Way, Swords, Co Dublin, K67F2K3. Recorded on P190021/S012, decision dated Oct 19, 2026.

Changes described in PMA records

P190021/S012: ReActiv8 Implantable Neurostimulation System

The FDA record for P190021/S012 describes a real-time process supplement to the ReActiv8 implantable neurostimulation system PMA held by Mainstay Medical Limited. The stated purpose is approval of revised magnetic resonance compatibility labeling in the ReActiv8 System Magnetic Resonance Imaging (MRI) Guidelines manual, now covering lead fragments up to 2 cm in length. The supplement carries a labeling-change reason tied to indications, instructions, shelf life, or tradename, and sits in the neuromuscular lower-back stimulator category for pain relief.

The identifier shows P190021 is the original PMA, so S012 is a supplement, not a new approval of the whole system. The record does not explain the prior lead-fragment limit, how the 2 cm figure was derived, or what testing supports it; the approval reflects the agency's labeling decision, not an independent finding of safety or clinical effectiveness reported here. Details on MRI field conditions and the full manual text remain absent from the supplied fields.

FDA approval-order wording

approval for revised magnetic resonance (MR) compatibility labeling in the ReActiv8 System Magnetic Resonance Imaging (MRI) Guidelines manual to include lead fragments up to 2 cm in length.

Oct 19, 2026 · Real-Time Process

P190021: ReActiv8 Implantable Neurostimulation System

FDA approved PMA P190021 for the ReActiv8 Implantable Neurostimulation System on June 16, 2020. The approval covers bilateral stimulation of the L2 medial branch of the dorsal ramus where it crosses the transverse process at L3, as an aid in managing intractable chronic low back pain associated with multifidus muscle dysfunction in adults who have failed pain medications and physical therapy and are not candidates for spine surgery.

The device is classified as a totally implanted neuromuscular stimulator for lower back muscles, product code QLK, under the neurology specialty. The applicant is Mainstay Medical Limited. The approval statement describes the intended patient population and stimulation target but does not itself provide independent proof of safety or clinical effectiveness.

FDA approval-order wording

Approval for the ReActiv8 System is indicated for bilateral stimulation of the L2 medial branch of the dorsal ramus as it crosses the transverse process at L3 as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy and are not candidates for spine surgery.

Jun 16, 2020

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Mainstay Medical LimitedPMA supplementOct 19, 2026FDA
Mainstay Medical LimitedPMA approvalJun 16, 2020FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.